LABP - Landos Biopharma shares fall 20% following analyst downgrades

Shares of Landos Biopharma (LABP -20.9%) are down today following downgrades by two Wall Street analysts. SVB Leerink's Thomas Smith downgraded shares to market perform from outperform, and cut his price target to $16 from $20 (14% upside). JonesTrading analyst Prakhar Agrawal cuts shares to hold from buy. Delays in trials for omilancor for Crohn's disease and NX-13 for ulceratie colitis "removes any stock-moving clinical catalyst in the next 12 months." Read about Landos Q3 2021 earnings results from yesterday.

For further details see:

Landos Biopharma shares fall 20% following analyst downgrades